Investment Landscape: Huntington's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Huntington's Disease research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 285
Active Trials (Recruiting/Active): 66
| Phase | Count |
|---|---|
| PHASE1 | 38 |
| PHASE1, PHASE2 | 18 |
| PHASE2 | 51 |
| PHASE2, PHASE3 | 6 |
| PHASE3 | 22 |
| PHASE4 | 3 |
| NA | 63 |
| Not Applicable | 78 |
| Status | Count |
|---|---|
| RECRUITING | 44 |
| ACTIVE_NOT_RECRUITING | 13 |
| NOT_YET_RECRUITING | 9 |
| COMPLETED | 157 |
| TERMINATED | 23 |
| WITHDRAWN | 3 |
Huntington's disease has 285 total clinical trials, making it one of the smallest neurodegenerative investment areas. The genetic certainty of HD makes it an attractive target, yet the limited Phase 3 portfolio (22 trials) indicates translational challenges. Recent gene-silencing successes offer hope for increased investment.
The historic approval of gene-silencing therapies has transformed HD investment landscape. Small molecule HTT inhibitors offer oral delivery advantages over ASOs. Mutant huntingtin lowering through multiple mechanisms remains a dominant focus. Neuronal calcium dysregulation targeting voltage-gated calcium channels represents a promising symptomatic approach with disease-modifying potential.
Only 7.7% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01